Issued 2026-08-13 at $132.28 · now $126.33 (2026-08-13, −4.5% since)
Based on its own history, a month from the 2026-08-13 close, INSM has typically landed between $109.10 and $164.42 — a range of −17.5% to +24.3% from the issuance price $132.28.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
4,978 overlapping 1 month windows · 2006-09-26 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($132.28) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where INSM has typically landed a month from the 2026-08-13 close of $132.28 — the range is history, not a prediction.
- now $126.33 (-4.5%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $133.08 (+0.6%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $121.93–$144.23
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $109.1–$164.42
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2011-07-08 | −71.7% | −71.7% | +0.0% |
| 2011-07-12 | −69.6% | −71.5% | +0.0% |
| 2011-07-11 | −68.2% | −71.1% | +1.5% |
| 3 best | |||
| 2024-05-24 | +204.3% | +0.0% | +216.9% |
| 2024-05-23 | +192.3% | −6.8% | +195.4% |
| 2024-05-22 | +188.5% | −8.9% | +188.5% |
4,978 overlapping windows · 2006-09-26 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2026-12-31 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) (source, as of 2026-08-14)
- 2028-12-28 — Trial primary completion: Phase 3 primary completion: A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) (source, as of 2026-08-14)
- 2028-12-30 — Trial primary completion: Phase 3 primary completion: Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (source, as of 2026-08-14)
- 2031-01-22 — Trial primary completion: Phase 3 primary completion: An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.